Protara Therapeutics Launches $100M Stock Offering via TD Cowen
Summary
Protara Therapeutics has entered into a sales agreement with TD Cowen for an At-The-Market (ATM) common stock offering of up to $100 million. This follows the company's recent S-3 shelf registration for up to $300 million and the 424B5 filing earlier today, which officially launched the $100 million ATM. The potential $100 million offering is highly dilutive, representing over a third of the company's current market capitalization. While it will extend the company's cash runway, which was $177.4 million in Q1, it will significantly impact per-share value for existing shareholders.
At the time of this announcement, TARA was trading at $4.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $267M. The 52-week trading range was $2.77 to $7.82. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.